HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Burt, M. Articles by Galicich, J. H. Search for Related Content PubMed PubMed Citation Articles by Burt, M. Articles by Galicich, J. H.

The Journal of Thoracic and Cardiovascular Surgery, Vol 103, 399-410, Copyright © 1992 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Resection of brain metastases from non-small-cell lung carcinoma. Results of therapy. Memorial Sloan-Kettering Cancer Center Thoracic Surgical Staff

M Burt, M Wronski, E Arbit and JH Galicich
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, N.Y. 10021.

The treatment of patients with a solitary brain metastasis has been evolving, with most centers recommending resection in patients with good performance status. To evaluate the results of resection of brain metastases from non-small-cell lung cancer, we reviewed our 16-year experience with 185 consecutive patients undergoing resection of brain metastases from 1974 to 1989, inclusive. There were 89 men and 96 women; ages ranged from 34 to 75 years (median 54). Sixty-five (35%) had synchronous and 120 (65%) metachronous brain metastases. Discounting the brain metastasis, 68 patients (37%) had stage I, 13 (7%) stage II, 62 (33%) stage IIIA, 30 (16%) stage IIIB, and 12 (6%) stage IV carcinoma. There was no significant difference in age, locoregional stage (TN), or histologic features in patients with synchronous versus metachronous lesions. The overall survival rates (n = 185) were as follows: 1 year, 55%; 2 years, 27%; 3 years, 18%; 5 years, 13%; and 10 years, 7% (median 14 months). There was no significant difference in survival between patients with synchronous and metachronous lesions. To evaluate the impact of locoregional stage and treatment of the primary site, we analyzed only those patients with synchronous brain metastases. Multivariate analysis demonstrated that locoregional stage had no significant effect on survival (p = 0.97), but complete resection of the primary disease significantly prolonged survival (p = 0.002). Therefore complete resection, and not stage, of the locoregional primary lesion is the primary determinant of survival in patients undergoing resection of brain metastases from non-small- cell lung cancer.

This article has been cited by other articles:

				K. R. Shen, B. F. Meyers, J. M. Larner, and D. R. Jones Special Treatment Issues in Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 290S - 305S. [Abstract] [Full Text] [PDF]

				M. G. Ewend, S. Brem, M. Gilbert, R. Goodkin, P. L. Penar, M. Varia, S. Cush, and L. A. Carey Treatment of Single Brain Metastasis with Resection, Intracavity Carmustine Polymer Wafers, and Radiation Therapy Is Safe and Provides Excellent Local Control Clin. Cancer Res., June 15, 2007; 13(12): 3637 - 3641. [Abstract] [Full Text] [PDF]

				O. Mercier, E. Fadel, M. de Perrot, S. Mussot, F. Stella, A. Chapelier, and P. Dartevelle Surgical treatment of solitary adrenal metastasis from non-small cell lung cancer J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 136 - 140. [Abstract] [Full Text] [PDF]

				J. Furak, I. Trojan, T. Szoke, L. Agocs, A. Csekeo, J. Kas, E. Svastics, J. Eller, and L. Tiszlavicz Lung Cancer and Its Operable Brain Metastasis: Survival Rate and Staging Problems Ann. Thorac. Surg., January 1, 2005; 79(1): 241 - 247. [Abstract] [Full Text] [PDF]

				A. Iwasaki, T. Shirakusa, Y. Yoshinaga, S. Enatsu, and M. Yamamoto Evaluation of the treatment of non-small cell lung cancer with brain metastasis and the role of risk score as a survival predictor Eur. J. Cardiothorac. Surg., September 1, 2004; 26(3): 488 - 493. [Abstract] [Full Text] [PDF]

				H. Vesselle, E. Turcotte, L. Wiens, R. Schmidt, J. E. Takasugi, T. Lalani, E. Vallieres, and D. E. Wood Relationship between Non-Small Cell Lung Cancer Fluorodeoxyglucose Uptake at Positron Emission Tomography and Surgical Stage with Relevance to Patient Prognosis Clin. Cancer Res., July 15, 2004; 10(14): 4709 - 4716. [Abstract] [Full Text] [PDF]

				V. Getman, E. Devyatko, D. Dunkler, F. Eckersberger, A. End, W. Klepetko, G. Marta, and M. R. Mueller Prognosis of patients with non-small cell lung cancer with isolated brain metastases undergoing combined surgical treatment Eur. J. Cardiothorac. Surg., June 1, 2004; 25(6): 1107 - 1113. [Abstract] [Full Text] [PDF]

				C.K. Connolly, P.E.Y. Van Schil, R. Milroy, O. Braendli, and R.J. Prescott The approach to the surgical management of cancer in four European countries Eur. Respir. J., November 1, 2003; 22(5): 838 - 844. [Abstract] [Full Text] [PDF]

				A. A. Vaporciyan, D. Rice, A. M. Correa, G. Walsh, J.B. Putnam, S. Swisher, R. Smythe, and J. Roth Resection of advanced thoracic malignancies requiring cardiopulmonary bypass Eur. J. Cardiothorac. Surg., July 1, 2002; 22(1): 47 - 52. [Abstract] [Full Text] [PDF]

				T. A. D'Amico, T. A. Aloia, M.-B. H. Moore, D. H. Conlon, J. E. Herndon II, M. S. Kinch, and D. H. Harpole Jr Predicting the sites of metastases from lung cancer using molecular biologic markers Ann. Thorac. Surg., October 1, 2001; 72(4): 1144 - 1148. [Abstract] [Full Text] [PDF]

				P. S. Billing, D. L. Miller, M. S. Allen, C. Deschamps, V. F. Trastek, and P. C. Pairolero Surgical treatment of primary lung cancer with synchronous brain metastases J. Thorac. Cardiovasc. Surg., September 1, 2001; 122(3): 548 - 553. [Abstract] [Full Text] [PDF]

				P. Granone, S. Margaritora, A. D'Andrilli, A. Cesario, K. Kawamukai, and E. Meacci Non-small cell lung cancer with single brain metastasis: the role of surgical treatment Eur. J. Cardiothorac. Surg., August 1, 2001; 20(2): 361 - 366. [Abstract] [Full Text] [PDF]

				H. Porte, J. Siat, B. Guibert, F. Lepimpec-Barthes, R. Jancovici, A. Bernard, A. Foucart, and A. Wurtz Resection of adrenal metastases from non-small cell lung cancer: a multicenter study Ann. Thorac. Surg., March 1, 2001; 71(3): 981 - 985. [Abstract] [Full Text] [PDF]

				J. D. Luketich and M. E. Burt Does Resection of Adrenal Metastases From Non-Small Cell Lung Cancer Improve Survival? Ann. Thorac. Surg., December 1, 1996; 62(6): 1614 - 1616. [Abstract] [Full Text]

				A. Mussi, M. Pistolesi, M. Lucchi, A. Janni, A. Chella, G. Parenti, G. Rossi, and C. A. Angeletti RESECTION OF SINGLE BRAIN METASTASIS IN NON-SMALL-CELL LUNG CANCER: PROGNOSTIC FACTORS J. Thorac. Cardiovasc. Surg., July 1, 1996; 112(1): 146 - 153. [Abstract] [Full Text]

				K. Yokoi, N. Miyazawa, and T. Arai Brain Metastasis in Resected Lung Cancer: Value of Intensive Follow-up With Computed Tomography Ann. Thorac. Surg., February 1, 1996; 61(2): 546 - 550. [Abstract] [Full Text]